ライフサイエンスコーパス: MBC

1 MBC performance was then evaluated using either complete

2 MBC study enrollment occurred within 4 weeks after the e

3 MBCs and antibodies recognizing pre-erythrocytic and cro

4 225 MBC samples were immunostained for HMG-CoAR and 124 were

5 was evaluated by immunohistochemistry in 289 MBC samples to assess their association.

6 nd against the bacteria tested, with a 0.37% MBC v/v for E. coli and 0.18% v/v for the other bacteria

7 axolide, and 4- methylbenzilidene camphor (4-MBC), were analyzed in the effluent of the aerobic gray

8 ple side methyl methyl groups (galaxolide, 4-MBC) required high energy input (Q </= 0.6 Ah/L) for tra

9 We assembled 446 MBCs on tissue microarrays and assessed clinicopathologi

10 Activated MBCs expressed high levels of activation markers and inc

11 Activated MBCs were also induced by TT booster immunization, indic

12 y in patients in the first-line and advanced MBC settings warrants further investigation.

13 efficacy in a model of postsurgical advanced MBC using a metastatic variant of the MDA-MB-231 triple-

14 the second-line or greater setting [advanced MBC]; 21 patients in the first-line setting [first-line

15 based formulations in patients with advanced MBC and NSCLC.

16 Patients with advanced MBC had received trastuzumab and a median of six prior n

17 s 41% overall, 33% in patients with advanced MBC, and 57% in first-line patients.

18 Despite their robust response to Ag, MBCs remain highly sensitive to FcgammaRIIB-mediated inh

19 ng burnout, which would be the result if all MBCs generated only terminal effector function.

20 ion between MBCs and naive B cells and among MBC subsets and how this leads to memory responses.

21 ptable toxicity in women with HER2-amplified MBC.

22 TCH with TH in patients with HER2-amplified MBC.

23 on and 1 shows bactericidal activity with an MBC of 6.25 mug/mL.

24 d Plasmodium falciparum (Pf)-specific Ab and MBC responses in two populations of children: (i) previo

25 Together plant belowground biomass and MBC explained 99.4% of variation in mean soil respiratio

26 Total gaseous C loss, CUE, and MBC were greater in the slow (ramp) warming treatment.

27 positively correlated with increased DOC and MBC.

28 oliferation in the developing cerebellum and MBCs and they identify the SHH:YAP:YB1:IGF2 axis as a po

29 The MPO MICs and MBCs for E. coli, P. aeruginosa, and S. aureus were sign

30 The evaluation of MICs and MBCs on 11 promysalin analogs, synthesized utilizing div

31 within the range of their in vitro MICs and MBCs.

32 inently expressed in primary human naive and MBCs, but expression strongly decreases during PC differ

33 itiation of BCR signaling in human naive and MBCs.

34 suggest that patients with BRCA1-associated MBC may show poor response to olaparib and illustrate th

35 Moreover, active atypical MBC positively correlated with proinflammatory cytokine

36 Malaria-exposed women had more atypical MBC and fewer marginal zone-like MBC, and their levels c

37 Classical but not atypical MBC were increased in P. falciparum infections.

38 st that the increased proportion of atypical MBC phenotypes found in HIV-1-infected individuals resul

39 Atypical MBCs express an array of inhibitory receptors and B cell

40 es suggests that classical MBCs and atypical MBCs differentiate in response to similar Ag-dependent s

41 iments indicated that activated and atypical MBCs were enriched in CMV-specific cells.

42 B cells that includes activated and atypical MBCs.

43 sponse to chronic malaria exposure, atypical MBCs appear to differentiate from classical MBCs becomin

44 eptor (BCR) signaling is stunted in atypical MBCs resulting in impaired B cell responses including pr

45 tion per se drives the expansion of atypical MBCs and phenotypically exhausted CD4 T cells, which has

46 Understanding the function of atypical MBCs and their relationship to classical MBCs will be cr

47 At present, the function of atypical MBCs in malaria is not known, nor are the factors that d

48 falciparum drives the expansion of atypical MBCs.

49 higher proportion of AMA1-specific atypical MBCs.

50 ge expansion of what we have termed atypical MBCs (CD19(+)/CD20(+)/CD21(-)/CD27(-)/CD10(-)).

51 n malaria-exposed children and that atypical MBCs do not express a unique V gene repertoire.

52 TNF-alpha)-producing cells, whereas atypical MBCs expressed high levels of inhibitory receptors and h

53 In this study, we investigated autoreactive MBC generation associated with this type of response.

54 he development and functions of autoreactive MBCs in lupus are poorly understood.

55 (MIC = 97.5 microg/mL) and was bactericidal (MBC = 187.5 microg/mL).

56 ut what determines whether GC B cells become MBCs or PCs.

57 ignificant metabolic differentiation between MBC samples from two different production sites in Campa

58 hat underlie differences in function between MBCs and naive B cells and among MBC subsets and how thi

59 y correlated with plant belowground biomass, MBC, soil temperature and soil moisture.

60 , revealing that the reaction engenders both MBC subsets with different immune effector function and,

61 solved organic C (DOC), microbial biomass C (MBC) and C accumulation in the heavy soil fraction in so

62 C (SOC), soil total N, microbial biomass C (MBC), microbial biomass N (MBN), water-soluble organic C

63 production of Mozzarella di Bufala Campana (MBC) is relevant for the agro-food economy of the Campan

64 ated HER2-positive metastatic breast cancer (MBC) and has demonstrated superior efficacy and improved

65 py, 125 women with metastatic breast cancer (MBC) completed a depression symptom measure (Center for

66 nts with suspected metastatic breast cancer (MBC) has significant prognostic and therapeutic implicat

67 Male breast cancer (MBC) is a rare hormone-driven disease often associated w

68 Male breast cancer (MBC) is rare.

69 ring patients with metastatic breast cancer (MBC) is unknown; however, data suggest that intensive mo

70 mutations found in metastatic breast cancer (MBC) promote ligand-independent receptor activation and

71 Metastatic breast cancer (MBC) remains an incurable illness in the majority of cas

72 ER2-overexpressing metastatic breast cancer (MBC) that progressed on trastuzumab-based therapy.

73 separate phase III metastatic breast cancer (MBC) trials, either alone or with chemotherapy, similarl

74 rvival outcomes in metastatic breast cancer (MBC) using a new quantitative multiplex assay (cMethDNA)

75 cally recurrent or metastatic breast cancer (MBC) was investigated in a three-arm, placebo-controlled

76 2 (HER2)-positive, metastatic breast cancer (MBC) who previously received trastuzumab and a taxane.

77 with HER2-positive metastatic breast cancer (MBC) who were previously treated with trastuzumab, we co

78 2 (HER2) -positive metastatic breast cancer (MBC) whose disease had progressed on HER2-targeted thera

79 nancies, including metastatic breast cancer (MBC), ovarian cancer, and advanced non-small cell lung c

80 atus in women with metastatic breast cancer (MBC).

81 ocally advanced or metastatic breast cancer (MBC).

82 eceptor 2-positive metastatic breast cancer (MBC).

83 with HER2-positive metastatic breast cancer (MBC).

84 poor prognosis in metastatic breast cancer (MBC).

85 d ATM-Chk2 signalings in male breast cancer (MBC).

86 2 (HER2) -positive metastatic breast cancer (MBC).

87 plus docetaxel in metastatic breast cancer (MBC).

88 for HER2-amplified metastatic breast cancer (MBC).

89 tuzumab-refractory metastatic breast cancer (MBC).

90 ut that decreasing microbial biomass carbon (MBC) is also important, and lower MBC at warmer temperat

91 d biomass and soil microbial biomass carbon (MBC), while high-level N additions decreased them.

92 4-methoxy-2, 2'-bipyrrole-5-carboxaldehyde (MBC).

93 Metaplastic breast carcinoma (MBC) is a rare histological breast cancer subtype charac

94 cells had a predominant classical (CD21(+)) MBC phenotype during both primary and chronic infections

95 ed distribution of peripheral memory B cell (MBC) subsets.

96 Recent studies characterizing memory B cell (MBC)-derived MAbs have provided valuable insight into th

97 ssed an activated (CD21(low)) memory B-cell (MBC) phenotype.

98 Memory B-cell (MBC) responses were assessed.

99 body-secreting cell (ASC) and memory B-cell (MBC) responses were enumerated in tonsils and blood.

100 or sustaining CGNP and medulloblastoma cell (MBC) proliferation.

101 ccination generates specific memory B cells (MBC) and long-lasting Ab responses.

102 can differentiate to become memory B cells (MBC), in which EBV persistence is established.

103 a cells and rapidly reactive memory B cells (MBC).

104 y-secreting cells (ASCs) and memory B cells (MBCs) after infection or vaccination.

105 clear whether the "atypical" memory B cells (MBCs) and "exhausted" CD4 T cells described in humans ex

106 on of FOXP1 in primary human memory B cells (MBCs) and B-cell lines, combined with chromatin immunopr

107 Memory B cells (MBCs) and long-lived plasma cells (LLPCs) persist after

108 t control differentiation of memory B cells (MBCs) and long-lived plasma cells (LLPCs).

109 Memory B cells (MBCs) are long-lived sources of rapid, isotype-switched

110 he acquisition of long-lived memory B cells (MBCs) is critical for the defense against many infectiou

111 n the surface of a subset of memory B cells (MBCs) located at sites of invading pathogens in mucosal

112 a large increase in atypical memory B cells (MBCs) that resemble B cells expanded in a variety of per

113 We comprehensively review memory B cells (MBCs), covering the definition of MBCs and their identit

114 long-lived plasma cells and memory B cells (MBCs), is remarkably inefficient, requiring years of mal

115 --properties associated with memory B cells (MBCs), which are typically generated via germinal center

116 tibody titers and long-lived memory B cells (MBCs), with the former deriving from long-lived plasma c

117 al (CD27(-)CD20(+)CD21(low)) memory B cells (MBCs).

118 ved plasma cells (LLPCs) and memory B cells (MBCs).

119 by generating plasma Abs and memory B cells (MBCs).

120 atypical and total activated memory B cells (MBCs).

121 igen-specific antibodies and memory B-cells (MBCs) during CPS-immunization and their correlation with

122 onally, active atypical and active classical MBC expressed higher levels of eotaxin receptor CCR3 tha

123 ypermutation rates of atypical and classical MBCs are indistinguishable indicating a common developme

124 with frequencies of activated and classical MBCs.

125 MBCs appear to differentiate from classical MBCs becoming refractory to BCR-mediated activation and

126 Although long-lived classical MBCs (CD19(+)/CD20(+)/CD21(+)/CD27(+)/CD10(-)) are gradu

127 in these repertoires suggests that classical MBCs and atypical MBCs differentiate in response to simi

128 cal MBCs and their relationship to classical MBCs will be critical to developing effective vaccines f

129 We describe a mixed base classifier (MBC) optimized to categorize the duration of subtype B i

130 persistently exposed children, their cognate MBCs were maintained at similar frequencies.

131 sistance surveillance specimens and compared MBC findings with those of serologic methods.

132 MIC and minimal bactericidal concentration (MBC) for 82 bacteria including E. coli, P. aeruginosa, S

133 ines the minimum bactericidal concentration (MBC) of immobilized antimicrobial peptides through a com

134 MIC) and minimum bactericidal concentration (MBC) values for these derivatives too were generally low

135 MIC) and minimum bactericidal concentration (MBC).

136 e their minimal bactericidal concentrations (MBC) against the spoilage food bacteria Escherichia coli

137 ml, and minimal bactericidal concentrations (MBC) in a range from 0.39 to 0.78 mg/ml.

138 Women with biopsy-confirmed MBC and not given trastuzumab for 2 mo or more underwent

139 In contrast, MBCs are generally thought to be long-lived.

140 een suggested that antibody isotype controls MBC differentiation upon restimulation.

141 eered mouse model (GEMM) for BRCA1-deficient MBC by introducing the MET proto-oncogene into a BRCA1-a

142 investigate the response of BRCA1-deficient MBCs to the PARP inhibitor olaparib.

143 To clarify functional roles for distinct MBC subsets during malaria infection, we generated tetra

144 the identity and function of these distinct MBC types.

145 ere also used to identify metabolites during MBC aging.

146 ctericidal activity compared to AgNO3 (i.e., MBC of 15ppm compared to 5ppm), and significantly lower

147 lls become poised to differentiate to either MBCs or PCs.

148 In ERalpha+ MBC, only AR had prognostic significance, suggesting AR

149 ts in human isotype-switched, IgG-expressing MBCs and compare them with those in IgM-expressing naive

150 Recently, FcRL4(+) MBCs were shown to be greatly increased in number in the

151 the rationale to combine the two agents for MBC treatment.

152 ted patients (median, seven prior agents for MBC; median follow-up, 17.4 months), the ORR was 34.5% (

153 ned with docetaxel as first-line therapy for MBC compared with docetaxel plus placebo.

154 enrolled (cohort 1: no prior trastuzumab for MBC and >/= 1 year from adjuvant trastuzumab, if given;

155 es of chemotherapy including trastuzumab for MBC and/or recurrence < 1 year from adjuvant trastuzumab

156 dian of six prior nonhormonal treatments for MBC; 86% of first-line MBC patients had received trastuz

157 ch that alters the nature of its output from MBCs to PCs as the response progresses.

158 response generated persistent and functional MBCs that share some, but not all, of the characteristic

159 f MBCs and their identities and subsets, how MBCs are generated, where they are localized, how they a

160 n of FOXP1 in B-cell lines and primary human MBCs represses their ability to differentiate into PCs.

161 We show that human MBCs are more robust than naive B cells at each step in

162 little is known about how Ags trigger human MBCs, even though our understanding of the molecular bas

163 Remarkably, we also identified MBC clones that recognized the mutant epitope better tha

164 PD-L2, independently of isotype, identified MBC subsets with distinct functions upon rechallenge.

165 d IgG(+) MBC subsets and an unmutated IgD(+) MBC population.

166 gnificant expansion of all switched (IgD(-)) MBC and a decrease of naive B cells.

167 ated immunoglobulin M(+) (IgM(+)) and IgG(+) MBC subsets and an unmutated IgD(+) MBC population.

168 onship between classical and atypical IgG(+) MBCs, we compared the Ab H and L chain V gene repertoire

169 d with immunoglobulin (Ig) M(+) MBCs, IgG(+) MBCs combine lower expression of FOXP1 with an enhanced

170 Thus, even in competition with IgG(+) MBCs, IgM(+) MBCs are rapid, plastic, early responders t

171 IgM(+) MBCs also gave rise to T cell-dependent IgM(+) and IgG(+

172 even in competition with IgG(+) MBCs, IgM(+) MBCs are rapid, plastic, early responders to a secondary

173 ally hypermutated Plasmodium-specific IgM(+) MBCs proliferated and gave rise to antibody-secreting ce

174 te pathway, the hormonal milieu and Hippo in MBC.

175 ease in SOC and total soil N, an increase in MBC and WSOC, and a decrease in MBN and WSON.

176 ive children showed significant increases in MBC counts after LAIV vaccination.

177 by EBV, thus favouring long-term latency in MBC and asymptomatic persistence.

178 to directly identify specific metabolites in MBC intact samples without time-consuming sample pre-tre

179 s a strong predictor of survival outcomes in MBC and may have clinical usefulness in risk stratificat

180 al results of bevacizumab plus paclitaxel in MBC.

181 eviously associated with shorter survival in MBC.

182 ection, uptake of (64)Cu-DOTA-trastuzumab in MBC is strongly associated with patient HER2 status and

183 demonstrated activity in a phase II trial in MBC.

184 characterise the metabolic profile of intact MBC samples and statistically distinguish the geographic

185 f these functions are compartmentalized into MBC subsets has remained unclear.

186 dynamical family as three of the five known MBCs, and the presence of ice on 24 Themis is strong evi

187 CD80(+)PD-L2(+) MBCs differentiated rapidly into AFCs but did not genera

188 l centers (GCs); conversely, CD80(-)PD-L2(-) MBCs generated few early AFCs but robustly seeded GCs.

189 re atypical MBC and fewer marginal zone-like MBC, and their levels correlated with both Plasmodium vi

190 rmonal treatments for MBC; 86% of first-line MBC patients had received trastuzumab in the (neo)adjuva

191 docetaxel did not improve TTP in first-line MBC treatment.

192 tients in the first-line setting [first-line MBC]) were enrolled.

193 ss carbon (MBC) is also important, and lower MBC at warmer temperatures is likely due to decreased ca

194 cally recurrent/metastatic breast cancer (LR/MBC).

195 received trastuzumab or chemotherapy for LR/MBC were stratified by prior adjuvant trastuzumab, prior

196 consistent with findings in HER2-negative LR/MBC, warranting prospective evaluation.

197 s with measurable/evaluable HER2-positive LR/MBC who had not received trastuzumab or chemotherapy for

198 r, as compared with immunoglobulin (Ig) M(+) MBCs, IgG(+) MBCs combine lower expression of FOXP1 with

199 ive signaling may play a role in maintaining MBC longevity.

200 streptococcal studies showed much higher MIC/MBC results, but such testing required lysed horse blood

201 h extreme use were hormone receptor-negative MBC (odds ratio [OR], 1.63; 95% CI, 1.27 to 2.08), histo

202 had measurable disease, and 45% had de novo MBC.

203 T cell help is required for activation of MBC but can be provided by naive T cells responding dire

204 led postmenopausal women with a diagnosis of MBC and prior exposure to an aromatase inhibitor.

205 spin-spin relaxation times and diffusion of MBC molecular components, respectively.

206 cascade seems to be active in a fraction of MBC patients and may represent a negative prognostic fac

207 In contrast, a large fraction of MBC produced antibody that recognized both wild-type (WT

208 In summary, the principle phenotype of MBC was luminal A, ductal, grade 2.

209 antibody produced by the polyclonal pool of MBC neutralized WT and variant viruses equivalently.

210 rate that in the absence of Ag, a portion of MBC receptors spontaneously oligomerized, and phosphoryl

211 s authenticity, traceability, and quality of MBC.

212 Recent studies of MBC development and function after protein immunization

213 The ability of MBCs to respond to variant viruses in vivo was confirmed

214 the earliest events in the Ag activation of MBCs and evidence for acquired cell-intrinsic difference

215 y B cells (MBCs), covering the definition of MBCs and their identities and subsets, how MBCs are gene

216 lopment of LLPCs, whereas differentiation of MBCs was unaffected.

217 A large fraction of MBCs harbor defects in breast cancer 1 (BRCA1).

218 on is associated with a limited induction of MBCs with effector potential.

219 nce, the differentiation and regeneration of MBCs are compartmentalized.

220 As compared to fresh samples, 2 days old MBC samples showed increasing signals for isobutylic alc

221 4 specimens classified by BED, the optimized MBC performed significantly better than a simple MBC (ag

222 2-positive locally advanced breast cancer or MBC were treated with 3.6 mg/kg T-DM1 plus pertuzumab (8

223 metary characteristics (main-belt comets, or MBCs), have blurred the line between comets and asteroid

224 Patients with HER2-overexpressing MBC who had progressed on trastuzumab-based therapy rece

225 th trastuzumab-resistant HER2-overexpressing MBC.

226 epidermal growth factor receptor 2-positive MBC, human epidermal growth factor receptor 2-targeted t

227 epidermal growth factor receptor 2-positive MBC.

228 nd D538G) in estrogen receptor (ER)-positive MBC and determine whether mutation is associated with in

229 Patients with ErbB2-positive MBC who experienced progression on prior trastuzumab-con

230 fety profile to patients with ErbB2-positive MBC.

231 Patients (N = 137) with HER2-positive MBC or recurrent locally advanced breast cancer were ran

232 t with T-DM1 for patients with HER2-positive MBC provided a significant improvement in PFS, with a fa

233 gent activity in patients with HER2-positive MBC who have previously received both approved HER2-dire

234 Six studies in patients with HER2-positive MBC who received T-DM1 3.6 mg/kg every 3 weeks and follo

235 e identified all patients with HER2-positive MBC who received T-DM1 after trastuzumab and pertuzumab

236 orts of trastuzumab-resistant, HER2-positive MBC, but one third of patients received therapy with T-D

237 tients with heavily pretreated HER2-positive MBC.

238 al treatment for most women with HR-positive MBC.

239 rapy as treatment for women with HR-positive MBC.

240 Women with hormone receptor-positive MBC were randomly assigned 1:1 in a multicenter, open-la

241 le improved PFS in hormone receptor-positive MBC, but this benefit was associated with a markedly inc

242 h acutely induced cells from the preexisting MBC pool.

243 0 mg/m2) in patients with heavily pretreated MBC.

244 milarly, Discriminant Analysis (DA) provided MBC group classification with 100% success in validation

245 Cross-reactive MBCs were detected before vaccination and expanded after

246 1-deficient mouse carcinosarcomas resembling MBC show intrinsic resistance to olaparib caused by incr

247 om a loss in the number of naive and resting MBCs rather than an increase in the number of atypical a

248 s results from the loss of naive and resting MBCs.

249 The loss of resting MBCs and naive B cells was mirrored in a population of c

250 tion, yet the specific and nonredundant role MBCs play in subsequent protection is unclear.

251 tein immunization have uncovered significant MBC heterogeneity.

252 performed significantly better than a simple MBC (agreement, 68.98% vs 67.13%).

253 s explaining 63.4% of the variation and soil MBC explaining the remaining 36%.

254 s of both plant belowground biomass and soil MBC.

255 The functional regulation of CMV-specific MBCs may limit the production of antibodies and the cont

256 Preexisting H3N2v-specific MBCs positively correlated with early increases in vacci

257 Long-lived murine Plasmodium-specific MBCs consisted of three populations: somatically hypermu

258 tetramers that identify Plasmodium-specific MBCs in both humans and mice.

259 cy and improved tolerability versus standard MBC treatments in randomized phase II and III studies.

260 of P. falciparum by performing standardized MBC enzyme-linked immunospot and enzyme-linked immunosor

261 cells adopt multiple fates upon stimulation, MBCs are more restricted in their responses.

262 Here we demonstrate that subcategorizing MBCs on the basis of their expression of CD80 and PD-L2,

263 r, in the case of secondary infections, such MBC-based approaches fail to distinguish acutely induced

264 n detecting osseous metastases for suspected MBC.

265 Women with suspected MBC evaluated with PET/CT and BSc (within 30 days) betwe

266 e scintigraphy (BSc) in women with suspected MBC.

267 Our data demonstrate that class-switched MBC can respond to variants of the original pathogen tha

268 formation, and fed it, along with synthetic MBC, to Streptomyces albus expressing redH and redG.

269 illar MBC responses correlated with systemic MBC and serological responses.

270 g BrdU pulse-labeling studies, we found that MBC formation preceded the formation of LLPCs in an adop

271 The MBC performance was optimal when secondary peaks on the

272 The MBC response can be activated following boost with Ag or

273 The behavior of the MBC was examined across a range of thresholds for callin

274 Evolving work reveals that the MBC compartment in mice and humans consists of distinct

275 distinct from ASCs and were committed to the MBC lineage.

276 If further validated, the MBC may prove beneficial for detecting recent infection

277 kills drug susceptible A. baumannii with the MBC of 2.0 mug/mL and an MDR A. baumannii with the MBC o

278 2.0 mug/mL and an MDR A. baumannii with the MBC of 3.13 mug/mL.

279 rong evidence that it also is present in the MBCs.

280 gnation of Origin (PDO) has been assigned to MBC in relation to its geographical origin.

281 Tonsillar MBC responses correlated with systemic MBC and serologic

282 t all, of the characteristics of traditional MBCs.

283 t in ER-positive aromatase inhibitor-treated MBC.

284 ned 97.54% of total variance between the two MBC groups for four metabolites (beta-galactose, beta-la

285 tally correct classification between the two MBC groups only for eCPMG spectra.

286 Whether MBCs homogeneously retain the ability to self-renew and

287 recognition, raising the question of whether MBCs are generated in this context.

288 n vivo was confirmed by experiments in which MBCs were adoptively transferred or depleted before seco

289 e synthesized and fed separately, along with MBC, to S. albus expressing redH and redG.

290 tients from 189 centers in 24 countries with MBC to exemestane plus placebo or exemestane plus everol

291 mprove the clinical outcome of patients with MBC pretreated with anthracyclines and taxanes.

292 A total of 1,221 patients with MBC previously treated with anthracycline and taxanes we

293 nostic significance of CTCs in patients with MBC receiving first-line chemotherapy.

294 are database was used to identify women with MBC diagnosed from 2002 to 2011 who underwent disease mo

295 th longer subsequent survival for women with MBC in this sample.

296 pproximately one third of elderly women with MBC were extreme users of disease-monitoring tests.

297 Women with MBC who had received prior anthracycline- and taxane-bas

298 with exemestane to postmenopausal women with MBC whose disease progresses while receiving nonsteroida

299 In multivariable models, among women with MBC, a high versus low CMI at week 4 was independently a

300 ] and radiographic imaging) among women with MBC.